Tarsus Pharmaceuticals, Inc. TARS

Key data

The business

Tarsus sells one drug that matters: Xdemvy, a prescription eye drop cleared by the FDA in July 2023 for Demodex blepharitis, an itchy, crusty eyelid condition caused by microscopic mites that colonize the lash line and leave tell-tale waxy collars at the base of the lashes. It is the first and only drug approved for the condition. A patient uses it twice a day for six weeks. The active ingredient, lotilaner, is the same mite-and-tick killer sold to veterinarians, licensed from Elanco for human use. It paralyzes the mite by jamming a nerve channel the drug's makers say human cells do not share (Saturn-1, NCT04475432, and Saturn-2, NCT04784091, the two pivotal trials). The moat is plain: Tarsus got there first, holds the patents, and no rival has an approved competitor. An eye-doctor sales force and a heavy direct-to-consumer campaign, the "Time to be seen" ads, do the rest. Behind Xdemvy sit early bets: oral lotilaner to prevent Lyme disease, in the Phase 2a Carpo trial, and a version aimed at rosacea.

The numbers

Two things to read past first. The revenue before 2024, $57M in 2021 fading to $17.4M in 2023, was collaboration and licensing income, not product. The Xdemvy story starts in late 2023. And Q4 2025 is not in the vendor feed, so the figures below are the full year less the reported nine months.

Product sales have climbed every quarter since launch, and the year-over-year rate is still enormous: Q2 2026's $173.9M is up 69% on the $102.7M of a year earlier. The more telling line is the loss. It narrowed for four straight quarters, from $20.3M down to $7.0M by Q1 2026, then jumped back to $18.6M in Q2, even as revenue rose another $12M. That is the inflection: the operating loss widened to $19.9M from $6.1M in a single quarter. Management stepped up demand-generation spend and, tellingly, began paying income tax, $2.7M in the quarter, a sign it now expects to owe money on profits it can see coming.

Zoom out and the shape is stark. Product revenue went from $17.4M in 2023, the launch year, to $183M in 2024 to $451M in 2025, and $336M in the first half of 2026 alone puts it on track to clear $700M. Gross margin runs about 90%, so nearly every new dollar of sales arrives as gross profit, and the only question that matters is how much of it management spends to grow. Wall Street's 2028 estimate, earnings of $4.72 a share on about $1.12B of revenue, implies a swing from today's loss to more than $200M of net income. At six times sales the market already credits most of that leverage. What it may not credit is the message in the Q2 spending jump: management is buying growth now and letting profit wait. The single print that settles the debate is Q3 2026, whether revenue reaccelerates while the operating loss stops widening.

Management

Founder-CEO Bobak Azamian, an MD and PhD, has the execution record to point to: he took a licensed veterinary molecule to the first approval in a new human indication and a $450M revenue ramp inside two years. The insider ledger, though, runs one way. Zero purchases in twelve months against 35 sales totaling $11.4M, with CFO Jeff Farrow selling $0.9M in June and Azamian himself about $1.6M across two March sales. The vendor feed does not carry the Form 4 plan status, so planned 10b5-1 selling cannot be split from discretionary here. Take the cluster as a flag, not a verdict. There is no dividend and no buyback. Every dollar of the drug's cash flow goes back into finding patients and funding the pipeline, and with no profit yet, pay tells you little.

How it fails or surprises you

Coverage and rebates squeeze the ramp. Xdemvy's net price depends on what insurers extract. As commercial and Medicare coverage broadens, gross-to-net rebates rise, so scripts can keep growing while net revenue per script falls. The first sign would be Q3 2026 sequential revenue growth slipping below the 7% it just posted, with net revenue per prescription flat or lower. Single-product ramps this steep have a way of meeting a coverage wall.

The widening loss. The Q2 2026 operating loss more than tripled to $19.9M even as revenue rose. If that spend does not convert into faster scripts, the 2028 profit the stock is priced on never arrives, and the story becomes a 90%-margin drug whose cash is consumed by ads. What would prove this memo wrong: Q3 opex holding near Q2's level while revenue growth decelerates rather than reaccelerates.

A second market opens (right tail). Behind the eye drop sits oral lotilaner to prevent Lyme disease, in the Phase 2a Carpo trial, plus a rosacea program. Lyme prevention is a large seasonal market with no vaccine in wide use, and the stock prices almost none of it. A clean Phase 2b readout or a Phase 3 start would hand Tarsus a second multi-billion-dollar shot the current $3.9B valuation barely counts.

Closing thoughts

Nothing about the science is in doubt. The drug is approved, it works, and Tarsus has the market to itself. What is unsettled is narrower and nearer: whether the money management is now pouring into advertising converts into durable, high-margin growth or leaks away against a coverage ceiling. The next quarter settles it: revenue growth and the operating loss. If revenue reaccelerates while the loss stops widening, the 2028 profit case is live and the rich multiple is defensible. If the loss widens again on slowing sales, you are paying a peak price for a decelerating ramp. The left tail is contained: an approved sole-supplier drug with $205M of cash rarely goes to zero, so the risk here is the valuation, not survival.

The bet is still that Tarsus keeps selling more Xdemvy to the millions of Americans who have the problem, and can keep spending heavily to find those patients and still come out ahead. What breaks it is a plateau, scripts leveling off while the advertising stays heavy. The pair of numbers that tells you first is next quarter's revenue growth set against the operating loss. Watch those two lines together, and the story tells on itself.